Veru Q1 Earnings Top Estimates

  • Veru Inc VERU reported a first-quarter FY22 sales decline of 3% year-on-year, to $14.13 million, beating the analyst consensus of $13 million.
  • U.S. FC2 prescription net revenues climbed 27% Y/Y to $11.6 million.
  • Gross profit rose 9% to $11.8 million, while the margin expanded 1000 basis points Y/Y to 84%.
  • The operating loss for the quarter was $(5) million.
  • EPS loss of $(0.08) beat the analyst consensus of $(0.12).
  • "In addition to securing additional telemedicine and internet pharmacy partners, we are actively constructing our own direct-to-patient telemedicine and internet pharmacy services platform to further increase the US prescription business," said CEO Mitchell Steiner.
  • The company held $116.1 million in cash and equivalents as of December 31, 2021.
  • Price Action: VERU shares traded lower by 0.88% at $5.60 in premarket on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsSmall CapBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!